Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Implantation tecnique

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Results are shown as regression coefficient with 95%-confidence intervals. *Adjusted for all parameters including age, sex, body mass index, diabetes mellitus, intrinsic platelet reac- tivity, platelet count, renal function (glomerular filtration rate), left ventricular function, smoking status, cytochrome P 450 2C19 *2 681G>A polymorphism, and cytochrome P 450 2C19 *17 806C>T polymorphism.

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Subgroup forest plot

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. MACE free survival Kaplan Meier curves stratified by clinical diagnosis leading to the demonstration of the IMA failure (acute myocardial infarction or ventricular tachycardia or not). A) IMA segment involved (anastomosis or not); B) over 120 months, respectively. Time = 0; IMA graft failure diagnostic cardiac catheterization.

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques: Biomarker Discovery, Diagnostic Assay

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Voltage map of the left atrium. A. After epicardial box ablation, before endocardial ablation. B. After endocardial ablation. Red circles show sites of endocardial ablation.

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1 Cumulative survival

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Independent predictors of ARB use

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1–2A, 2B. Left side: PAP and PAWP. Right side (same scale): simultaneous LV-RV pres- sure. LVEDP/RVEDP at yellow/green arrow tip.

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1 - Set up of pedal ergometer

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Survival of HPAH

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. DOX cardiotoxicity a: echo, b: ascites, c: karyolysis, myofibril loss; DOX+TAU group d: inactive fibroblasts, reduced degeneration.

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Top panel: Adverse event rates in a cohort of 251 patients with moderate MAVD; symp- toms (red), aortic valve replacement (green) and cardiac death (blue). Bottom panel: Adverse event rates between 117 selected patients with moderate mixed aortic valve disease and matched controls. (A) MAVD (red) and isolated moderate aortic regurgitation group (blue). (B) MAVD (red) and isolated moderate aortic stenosis group (green). (C) MAVD (red) and isolated severe aortic stenosis group (light blue). Mavd: Mixed aortic valve disease; AR: Aortic regurgitation; AS: Aortic stenosis; AVR: Aortic valve replacement

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques: Isolation

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Long-term survival after SAVR

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Kaplan-Meier Survial analysis for MACE.

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Complications vs disease severity

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Comparison of thromboembolic event rates. (A) History of atrial fibrillation [blue] (include the patients with atrial fibrillation alone and those with a combination of atrial fibrillation and atrial flutter) vs atrial flutter/IART [red] (patients without any history of atrial fibrillation). (B) Antiplatelet therapy [blue] (aspirin alone excluding other antiplatelet agents) vs anticoagulation therapy [red] (warfarin with or without antiplatelet therapy). (C) Composite adverse event between the patients with history of thromboembolic event (red) vs patients without history of thromboembolic events (blue) Iart: Intraatrial reentry tachycardia

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques: Comparison

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Kaplan-Meier analysis indicates a higher mortality rate amongst survivors of SCD (blue line) when compared to an age-, gender and disease-matched control population (green line). Five year survival was 76% for survivors of SCD when compared to 98% for the control population (log-rank test P=0.002).

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques: Control

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Long term follow-up after acute myocardial infarction

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1 (continued). Long term follow-up after acute myocardial infarction

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. A: Women and men show similar ratings in all PHQ-9 items. B: PHQ-9>9 is associated with an increased all-cause mortality risk in women and men (left) and with an increased risk of rehospitalization only in men (right). PHQ-9, 9-item Patient Health Questionnaire; f, female; m, male.

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Medians with corresponding 95% CI of biomarkers at baseline, discharge, 1 and 6 months in patients with ST-elevation- (STEMI) and non-ST elevation (NSTEMI) myocardial infarc- tion according to complete procedural success.

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Kaplan-Meier analysis of the c

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Unadjusted (top) and adjusted (bottom) 3-year mortality hazards.

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Survival by the CHA2DS2VASC score

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. SYNTAX and GENSINI correlation

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques:

Journal: European Heart Journal

Article Title: Tuesday 30 August 2016

doi: 10.1093/eurheartj/ehw434

Figure Lengend Snippet: Figure 1. Differences in 2-year adjusted mortality risk between regions.

Article Snippet: Using a neutralizing anti-murine IL-1β antibody (Novartis), the activity of IL-1β was inhibited at different time points after CVB3 infection.

Techniques: